Details of the Drug

General Information of Drug (ID: DMTI8YE)

Drug Name
Bosutinib
Synonyms
SKI 606; SKI606; Bosutinib (USAN); PF-5208763; SKI-606; Xy]-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propo; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib (BCR-ABL inhibitor 3rd gen)
Indication
Disease Entry ICD 11 Status REF
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive N.A. Approved [1]
Breast cancer 2C60-2C65 Approved [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 530.4
Logarithm of the Partition Coefficient (xlogp) 5.4
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 3650 mcgh/L []
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 200 mcg/L []
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 4-6 h []
Half-life
The concentration or amount of drug in body reduced by one-half in 22.5 hours [3]
Metabolism
The drug is metabolized via the CYP3A4 []
Vd
The volume of distribution (Vd) of drug is 6080 +/- 1230 L []
Chemical Identifiers
Formula
C26H29Cl2N5O3
IUPAC Name
4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile
Canonical SMILES
CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC
InChI
InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)
InChIKey
UBPYILGKFZZVDX-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5328940
ChEBI ID
CHEBI:39112
CAS Number
380843-75-4
DrugBank ID
DB06616
TTD ID
D0OB0F
VARIDT ID
DR00253
INTEDE ID
DR0224
ACDINA ID
D00075
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proto-oncogene c-Src (SRC) TT6PKBN SRC_HUMAN Inhibitor [4]
Tyrosine-protein kinase ABL1 (ABL) TT3PJMV ABL1_HUMAN Inhibitor [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Protein Interaction/Cellular Processes [7]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Post-Translational Modifications [8]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Gene/Protein Processing [9]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Gene/Protein Processing [8]
Proto-oncogene tyrosine-protein kinase Src (SRC) OTETYX40 SRC_HUMAN Post-Translational Modifications [8]
Tyrosine-protein kinase ABL1 (ABL1) OT09YVXH ABL1_HUMAN Gene/Protein Processing [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
ICD Disease Classification
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tyrosine-protein kinase ABL1 (ABL) DTT ABL1 9.65E-34 0.48 1.49
P-glycoprotein 1 (ABCB1) DTP P-GP 4.70E-06 -5.80E-02 -1.98E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 7.29E-03 -3.47E-02 -1.80E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Bosutinib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Bosutinib and Eribulin. Breast cancer [2C60-2C6Y] [11]
HKI-272 DM6QOVN Moderate Decreased clearance of Bosutinib due to the transporter inhibition by HKI-272. Breast cancer [2C60-2C6Y] [11]
Tucatinib DMBESUA Major Decreased metabolism of Bosutinib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [12]
Alpelisib DMEXMYK Moderate Decreased clearance of Bosutinib due to the transporter inhibition by Alpelisib. Breast cancer [2C60-2C6Y] [11]
Coadministration of a Drug Treating the Disease Different from Bosutinib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Bosutinib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [12]
Sarecycline DMLZNIQ Moderate Decreased clearance of Bosutinib due to the transporter inhibition by Sarecycline . Acne vulgaris [ED80] [11]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Bosutinib and Ivosidenib. Acute myeloid leukaemia [2A60] [13]
Arn-509 DMT81LZ Major Increased metabolism of Bosutinib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [14]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Bosutinib and Gilteritinib. Acute myeloid leukaemia [2A60] [15]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Bosutinib and Ivabradine. Angina pectoris [BA40] [11]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Bosutinib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [16]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Bosutinib and Levalbuterol. Asthma [CA23] [17]
Troleandomycin DMUZNIG Major Decreased metabolism of Bosutinib caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [12]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Bosutinib and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [18]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Bosutinib and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [19]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Bosutinib and Olodaterol. Chronic obstructive pulmonary disease [CA22] [20]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Bosutinib and Vilanterol. Chronic obstructive pulmonary disease [CA22] [17]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Bosutinib and Pasireotide. Cushing syndrome [5A70] [21]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Bosutinib and Osilodrostat. Cushing syndrome [5A70] [11]
Lumacaftor DMCLWDJ Major Increased metabolism of Bosutinib caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [11]
Ivacaftor DMZC1HS Moderate Decreased clearance of Bosutinib due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [11]
MK-8228 DMOB58Q Major Decreased metabolism of Bosutinib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [12]
SODIUM CITRATE DMHPD2Y Moderate Decreased absorption of Bosutinib due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [11]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Bosutinib and Deutetrabenazine. Dystonic disorder [8A02] [22]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Bosutinib and Ingrezza. Dystonic disorder [8A02] [23]
Stiripentol DMMSDOY Major Decreased metabolism of Bosutinib caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [12]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Bosutinib caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [14]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Bosutinib and Cannabidiol. Epileptic encephalopathy [8A62] [11]
Tazemetostat DMWP1BH Moderate Increased metabolism of Bosutinib caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [24]
Boceprevir DMBSHMF Major Decreased metabolism of Bosutinib caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [12]
Daclatasvir DMSFK9V Moderate Decreased clearance of Bosutinib due to the transporter inhibition by Daclatasvir. Hepatitis virus infection [1E50-1E51] [11]
GS-5885 DMSL3DX Moderate Decreased clearance of Bosutinib due to the transporter inhibition by GS-5885. Hepatitis virus infection [1E50-1E51] [11]
GS-9857 DMYU6P5 Moderate Decreased clearance of Bosutinib due to the transporter inhibition by GS-9857. Hepatitis virus infection [1E50-1E51] [11]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Bosutinib and Brentuximab vedotin. Hodgkin lymphoma [2B30] [25]
Cobicistat DM6L4H2 Major Decreased metabolism of Bosutinib caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [12]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Bosutinib and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [11]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Bosutinib and Teriflunomide. Hyper-lipoproteinaemia [5C80] [26]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Bosutinib and BMS-201038. Hyper-lipoproteinaemia [5C80] [27]
Levamlodipine DM92S6N Moderate Decreased metabolism of Bosutinib caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [11]
Berotralstat DMWA2DZ Major Decreased metabolism of Bosutinib caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [12]
Suvorexant DM0E6S3 Moderate Decreased clearance of Bosutinib due to the transporter inhibition by Suvorexant. Insomnia [7A00-7A0Z] [11]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Bosutinib and Polyethylene glycol. Irritable bowel syndrome [DD91] [11]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Bosutinib and Denosumab. Low bone mass disorder [FB83] [28]
Crizotinib DM4F29C Major Decreased metabolism of Bosutinib caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [12]
Brigatinib DM7W94S Moderate Decreased clearance of Bosutinib due to the transporter inhibition by Brigatinib. Lung cancer [2C25] [11]
Ceritinib DMB920Z Major Decreased metabolism of Bosutinib caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [12]
PF-06463922 DMKM7EW Major Increased metabolism of Bosutinib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [14]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Bosutinib and Osimertinib. Lung cancer [2C25] [29]
Capmatinib DMYCXKL Moderate Decreased clearance of Bosutinib due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [11]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Bosutinib and Selpercatinib. Lung cancer [2C25] [11]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Bosutinib and Lumefantrine. Malaria [1F40-1F45] [12]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Bosutinib and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [30]
Idelalisib DM602WT Major Decreased metabolism of Bosutinib caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [12]
IPI-145 DMWA24P Major Decreased metabolism of Bosutinib caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [12]
Ibrutinib DMHZCPO Moderate Decreased clearance of Bosutinib due to the transporter inhibition by Ibrutinib. Mature B-cell lymphoma [2A85] [11]
Ponatinib DMYGJQO Moderate Decreased clearance of Bosutinib due to the transporter inhibition by Ponatinib. Mature B-cell lymphoma [2A85] [11]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Bosutinib and Vemurafenib. Melanoma [2C30] [21]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Bosutinib and LGX818. Melanoma [2C30] [31]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Bosutinib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [11]
Lasmiditan DMXLVDT Moderate Decreased clearance of Bosutinib due to the transporter inhibition by Lasmiditan. Migraine [8A80] [32]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Bosutinib and Tecfidera. Multiple sclerosis [8A40] [33]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Bosutinib and Siponimod. Multiple sclerosis [8A40] [12]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Bosutinib and Fingolimod. Multiple sclerosis [8A40] [34]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Bosutinib and Ocrelizumab. Multiple sclerosis [8A40] [35]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Bosutinib and Ozanimod. Multiple sclerosis [8A40] [11]
Fedratinib DM4ZBK6 Major Decreased metabolism of Bosutinib caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [12]
Rolapitant DM8XP26 Moderate Decreased clearance of Bosutinib due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [36]
Netupitant DMEKAYI Major Decreased metabolism of Bosutinib caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [12]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Bosutinib and Entrectinib. Non-small cell lung cancer [2C25] [12]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Bosutinib and Rucaparib. Ovarian cancer [2C73] [11]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Bosutinib and Triclabendazole. Parasitic worm infestation [1F90] [11]
Istradefylline DM20VSK Moderate Decreased metabolism of Bosutinib caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [11]
Abametapir DM2RX0I Moderate Decreased metabolism of Bosutinib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [37]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Bosutinib and Macimorelin. Pituitary gland disorder [5A60-5A61] [38]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Bosutinib and Degarelix. Prostate cancer [2C82] [11]
Enzalutamide DMGL19D Major Increased metabolism of Bosutinib caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [14]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Bosutinib and Golimumab. Rheumatoid arthritis [FA20] [39]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Bosutinib when combined with Anthrax vaccine. Sepsis [1G40-1G41] [40]
Voxelotor DMCS6M5 Major Decreased metabolism of Bosutinib caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [12]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Bosutinib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [11]
Larotrectinib DM26CQR Moderate Decreased metabolism of Bosutinib caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [11]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Bosutinib and LEE011. Solid tumour/cancer [2A00-2F9Z] [21]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Bosutinib and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [11]
Fostamatinib DM6AUHV Moderate Decreased clearance of Bosutinib due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [41]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Bosutinib and Lenvatinib. Thyroid cancer [2D10] [11]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Bosutinib and Cabozantinib. Thyroid cancer [2D10] [11]
⏷ Show the Full List of 82 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Magnesium stearate E00208 11177 lubricant
Poloxamer 188 E00645 Not Available Emulsifying agent; Solubilizing agent; Surfactant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Haematite red E00236 14833 Colorant
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 13 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Bosutinib Monohydrate eq 400mg base tablet eq 400mg base Tablet Oral
Bosutinib Monohydrate eq 500mg base tablet eq 500mg base Tablet Oral
Bosutinib Monohydrate eq 100mg base tablet eq 100mg base Tablet Oral
Bosutinib 100 mg tablet 100 mg Oral Tablet Oral
Bosutinib 400 mg tablet 400 mg Oral Tablet Oral
Bosutinib 500 mg tablet 500 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Bosutinib FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5710).
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
5 In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib. J Hematol Oncol. 2015 Jul 7;8:81.
6 In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
7 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
8 SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res. 2006 Feb 15;66(4):2279-86. doi: 10.1158/0008-5472.CAN-05-2057.
9 Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. Arch Toxicol. 2022 Jul;96(7):1975-1987. doi: 10.1007/s00204-022-03291-5. Epub 2022 Apr 18.
10 In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006 Dec 1;66(23):11314-22. doi: 10.1158/0008-5472.CAN-06-1199. Epub 2006 Nov 17.
11 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12 Cerner Multum, Inc. "Australian Product Information.".
13 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
14 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
15 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
16 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
17 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
18 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
19 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
20 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
21 Canadian Pharmacists Association.
22 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
23 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
24 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
25 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
26 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
27 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
28 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
29 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
30 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
31 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
32 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
33 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
34 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
35 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
36 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
37 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
38 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
39 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
40 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
41 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.